Home › Research › Treatments
Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance
Monia Donati, Angelo Sabato Boccia, Fabrizio De Ponti, Elisabetta Poluzzi, Emanuel Raschi. Alzheimer s Research & Therapy, 2025-04-11
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
The anti-amyloid monoclonal antibody lecanemab received the US accelerated approval for mild cognitive impairment or mild dementia stage of Alzheimer disease in January 2023, which was converted into traditional approval in June 2023. However, its regulatory assessment in Europe is still ongoing, and the European Commission has asked the Committee for Medicinal Products for Human Use of the European Medicines Agency to consider an update on the safety of lecanemab. Thus, timely post-marketing real-life studies are essential to clarify its long-term safety profile and to establish relevant place in therapy. In this regard, a recent study by Xing et al., analyzed individual case safety reports (ICSRs) collected in the Food and Drug Administration Adverse Event Reporting System (FAERS), a consolidated pharmacovigilance archive. In this Matters Arising article, we highlighted important methodological aspects that should not be overlooked by clinicians who are not fully familiar with this kind of study (the so-called disproportionality analysis through the case/non-case design), thus supporting enhanced awareness of stakeholders on interpretation, limitations and opportunities of FAERS data. To this end, we focused on the unexpected signal of pancreatic carcinoma raised by Xing et al., attempted to replicate the statistical findings and also provided a descriptive inspection of ICSRs: these are current rights and duties of modern pharmacovigilance to ensure evidence-based decision making.
What this study adds
Evidence grade: Low
This article discusses how safety data on lecanemab after approval should be collected and interpreted, noting that regulatory review in Europe is still ongoing. It stresses that real-life post-marketing studies are needed to clarify the drug's long-term safety and its place in treatment.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Donati, M., Boccia, A. S., De Ponti, F., Poluzzi, E., & Raschi, E. (2025). Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance. Alzheimer s Research & Therapy. https://doi.org/10.1186/s13195-025-01699-6
Vancouver
Donati M, Boccia AS, De Ponti F, Poluzzi E, Raschi E. Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance. Alzheimer s Research & Therapy. 2025. doi:10.1186/s13195-025-01699-6. PMID: 40217276.
BibTeX
@article{donati2025-40217276,
author = {Donati, Monia and Boccia, Angelo Sabato and De Ponti, Fabrizio and Poluzzi, Elisabetta and Raschi, Emanuel},
title = {{Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance}},
journal = {Alzheimer s Research \& Therapy},
year = {2025},
doi = {10.1186/s13195-025-01699-6},
pmid = {40217276},
url = {https://doi.org/10.1186/s13195-025-01699-6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- However, its regulatory assessment in Europe is still ongoing, and the European Commission has asked the Committee for Medicinal Products for Human Use of the European Medicines Agency to consider an update on the safety of lecanemab.
- Thus, timely post-marketing real-life studies are essential to clarify its long-term safety profile and to establish relevant place in therapy.
- In this regard, a recent study by Xing et al., analyzed individual case safety reports (ICSRs) collected in the Food and Drug Administration Adverse Event Reporting System (FAERS), a consolidated pharmacovigilance archive.
- In this Matters Arising article, we highlighted important methodological aspects that should not be overlooked by clinicians who are not fully familiar with this kind of study (the so-called disproportionality analysis through the case/non-case design), thus supporting enhanced awareness of stakeholders on interpretation, limitations and opportunities of FAERS data.
- To this end, we focused on the unexpected signal of pancreatic carcinoma raised by Xing et al., attempted to replicate the statistical findings and also provided a descriptive inspection of ICSRs: these are current rights and duties of modern pharmacovigilance to ensure evidence-based decision making.
Why it matters
This article discusses how safety data on lecanemab after approval should be collected and interpreted, noting that regulatory review in Europe is still ongoing. It stresses that real-life post-marketing studies are needed to clarify the drug's long-term safety and its place in treatment.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 36/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Alzheimer s Research & Therapy) |
| Journal's citation record | 1 / 4 | Alzheimer s Research & Therapy: journal h-index 146 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 4 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.5× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 4 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Emanuel Raschi: h-index 48 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Bologna: institution h-index 989 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40217276) |
| Free to read | 2 / 2 | Free to read |
| Total | 36 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1186/s13195-025-01699-6
- PubMed: 40217276
- Original source →
- Free full text: Alzheimer s Research & Therapy →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.